Journal of the Canadian Urological Association
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Testosterone therapy at the time of vasectomy reversal
2024
-
2022 American Society of Clinical Oncology (ASCO): Meeting highlights
2022
-
The role of bariatric surgery on kidney transplantation: A systematic review and meta-analysis
2021
-
Bone scan use in the management of metastatic castration-resistant prostate cancer: Survey of practice patterns among Canadian radiation oncologists, medical oncologists, and urologists
2020
-
Androgen receptor axis-targeted agents
2016
-
Chemotherapy research for metastatic prostate cancer
2016
-
Localized prostate cancer
2016
-
Radionulcides
2016
-
Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update (vol 3, pg 200, 2009)
2009
-
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma
2007
-
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma
2007
-
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects
2007
-
Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: Moving to guidelines
2007
-
Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines
2007
-
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma..
18:E371-E386.
2024
-
Case – Biotin supplements interfering with prostate-specific antigen assays.
18:E365-E367.
2024
-
Length of hospital stay and procedure time after partial nephrectomy or percutaneous thermal ablation: A systematic review and meta-analysis..
19.
2024
-
Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis..
19.
2024
-
Predictors of failed same-day discharge in patients undergoing robot-assisted radical prostatectomy in a Canadian universal healthcare system.
18:316-320.
2024
-
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer..
19.
2024
-
Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE)..
18:E194-E203.
2024
-
2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium.
18:E179-86.
2024
-
Addressing controversial areas in the management of advanced prostate cancer in Canada.
18:E127-E137.
2024
-
Point-of-care-ultrasound for the assessment of post-renal transplant recipients.
18:110-114.
2024
-
Predictors of disease recurrence in high-risk non-metastatic renal cell carcinoma patient’s post-surgical resection.
18:E53-E58.
2024
-
Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE).
18.
2024
-
Images in urology – Metastatic urothelial carcinoma of the right vastus lateralis following robotic-assisted radical cystectomy.
18:E37-E39.
2024
-
2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.
17:314-25.
2023
-
Erratum: 2023 CKCF consensus statement.
17:E337-E337.
2023
-
Genetic testing practices among specialist physicians who treat prostate cancer.
17:326-336.
2023
-
Minimizing the learning curve for robotic-assisted radical cystectomy.
17:E252-E256.
2023
-
2023 Canadian Urological Association guideline: Evaluation and management of azoospermia.
17:228-240.
2023
-
The impact of tranexamic acid on perioperative outcomes in urological surgeries: A systematic review and meta-analysis.
17:205-216.
2023
-
Adjuvant therapy for renal cell carcinoma.
17:E154-63.
2023
-
UroBOT: A national survey of Canadian urology residents and fellows on robot-assisted surgery.
17:E121-E127.
2023
-
First Canadian experience with same-day discharge after robot-assisted radical prostatectomy.
17:39-43.
2023
-
2022 European Society for Medical Oncology: Meeting highlights.
16:E590-6.
2022
-
UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer.
16:E581-E589.
2022
-
2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).
16:E506-15.
2022
-
Case – The folly of a misplaced Foley.
16:E569-E571.
2022
-
Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada.
16:E516-E522.
2022
-
Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.
16:321-332.
2022
-
Survey of Canadian urology residency programs: Perception of virtual education during the COVID-19 pandemic and beyond.
16:273-8.
2022
-
UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text).
16:E416-31.
2022
-
Canadian Urological Association best practice report: Diagnosis and management of nocturia.
16:E336-E349.
2022
-
Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.
16:155-73.
2022
-
Matching to urology during the COVID-19 pandemic and with the Association of Faculties of Medicine of Canada electives diversification policy: Survey of the 2021 urology Canadian Residency Matching Service applicants.
16:228-230.
2022
-
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
16:132-143.
2022
-
Predictors of success after bilateral epididymovasostomy performed during vasectomy reversal: A multi-institutional analysis.
16:E132-E136.
2022
-
Authorship error/Affiliation error.
16:E111-E111.
2022
-
Canadian Urological Association guideline: Management of small renal masses – Full-text.
16:E61-75.
2022
-
Canadian Urological Association guideline: Management of small renal masses – Summary of recommendations.
16:24-5.
2022
-
Development and initial validation of a cost-effective, re-usable, ultrasound-compatible suprapubic catheter insertion training simulator.
16:63-69.
2022
-
Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A call to action.
16:15-15.
2022
-
The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients.
16:48-54.
2022
-
Canadian Urologic Association best practice report: Bone health in prostate cancer.
15:375-382.
2021
-
Pediatric Urologists of Canada (PUC) 2021 position statement: Differences of sex development (AKA disorders of sex development).
15:395-396.
2021
-
The impact of cannabis use on male sexual function: A 10-year, single-center experience.
15:E652-E657.
2021
-
Use of cannabis in urological cancer patients: A review to evaluate risk for cancer development, therapeutic use, and symptom management.
15:413-419.
2021
-
Case – Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation.
15:E620-E621.
2021
-
Canadian consensus forum of key controversial areas in the management of advanced prostate cancer.
15:353-358.
2021
-
The chicken or the egg: Longitudinal changes in pain and catastrophizing in women with interstitial cystitis/bladder pain syndrome.
15:326-331.
2021
-
Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer.
15:E424-E460.
2021
-
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version.
15:230-9.
2021
-
Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma.
15:281-286.
2021
-
Case – 18F-DCFPyL-positron emission tomography/computed tomography (PET/CT) time of imaging.
15:E376-E379.
2021
-
Practice-changing publications in functional urology: A case-based approach.
15:E330-4.
2021
-
Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: A review of current publications and Canadian data.
15:202-206.
2021
-
Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.
15:162-172.
2021
-
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.
15:E307-E322.
2021
-
Message from the CUA 2021 Scientific Committee.
15:S46-7.
2021
-
Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study.
15:181-186.
2021
-
The development and efficacy of an interdisciplinary chronic pelvic pain program.
15:E323-E328.
2021
-
Development, implementation, and evaluation of a competency-based didactic and simulation-focused boot camp for incoming urology residents: Report of the first three years.
15:98-105.
2021
-
Easing the transition to residency through urology bootcamp.
15:107-107.
2021
-
Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.
15:84-97.
2021
-
Point-of-care ultrasound in urology: Design and evaluation of a feasible introductory training program for Canadian residents.
15:E210-E214.
2021
-
“I think I’ve seen this before” – Reflecting on improving readiness for residency with a urology bootcamp.
15:106-106.
2021
-
Case – Resolution of urethral mesh perforation after sling: The migrating mesh.
15:E184-E186.
2021
-
Images – Rare diagnosis of high-grade, undifferentiated pelvic sarcoma for urinary dysfunction in a young man.
15:E192-E194.
2021
-
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text).
15:E81-9.
2021
-
Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial.
15:E97-E102.
2021
-
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.
15:E90-E96.
2021
-
Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction: A Cochrane review.
14:423-430.
2020
-
Canadian Urological Association Best Practice Report: Holmium: YAG laser eye safety.
14:380-382.
2020
-
Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC.
14:E616-E620.
2020
-
Surveillance post-radiofrequency ablation for small renal masses: Recurrence and followup.
14:398-403.
2020
-
Canadian Urological Association Best Practice Report: Diagnosis and management of sporadic angiomyolipomas.
14:E527-E536.
2020
-
Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada.
14:E588-E593.
2020
-
Navigating urology’s new normal and mitigating the effects of a second wave of COVID-19.
14:E543-E548.
2020
-
Canadian Urological Association guideline on male urethral stricture.
14:305-316.
2020
-
Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes.
14:337-345.
2020
-
Acute care for renal colic in Canadian healthcare — a commentary on emergency department patient flow metrics and treatment options.
14:265-266.
2020
-
Economic evaluation of robot-assisted radical prostatectomy compared to open radical prostatectomy for prostate cancer treatment in Ontario, Canada.
14:E350-E357.
2020
-
Pediatric Urological Surgery Readiness Condition (PedsUROCON).
14:E290-E293.
2020
-
A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association.
14:163-168.
2020
-
Prioritization and management recommendations of paediatric urology conditions during the COVID-19 pandemic.
14:E237-E250.
2020
-
Urology education in the time of COVID-19.
14:E231-E232.
2020
-
How to prioritize urological surgeries during epidemics: Lessons learned from the Toronto SARS outbreak in 2003.
14:E159-E160.
2020
-
Patient-reported pain, discomfort, and anxiety during magnetic resonance imaging-targeted prostate biopsy.
14:E202-E208.
2020
-
Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic.
14:E154-E158.
2020
-
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer.
14:123-130.
2020
-
A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.
14:130-138.
2020
-
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum.
14:E137-E149.
2020
-
The opioid crisis and nudge theory.
14:139-140.
2020
-
Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
14:E115-E125.
2020
-
Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.
14:E57-E64.
2020
-
Antagonizing GnRH receptors: A temporary ADT salvage maneuver for prostate cancer patients experiencing PSA failure with GnRH agonist.
14:42.
2020
-
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.
14:17-23.
2020
-
Management algorithms for metastatic prostate cancer.
13:50-60.
2020
-
A prospective, randomized, pilot trial of a polyethylene glycol (PEG)-coated collagen patch (Hemopatch®) for intraoperative hemostasis during deceased donor renal transplant.
14:E1-E5.
2020
-
Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.
13:396-403.
2019
-
Enhancing diversity or upping uncertainty?.
13:430.
2019
-
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.
13:318-327.
2019
-
Depression and helplessness impact interstitial cystitis/bladder pain syndrome pain over time.
13:328-33.
2019
-
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.
13:343-54.
2019
-
Canadian Urological Association guideline: Muscle-invasive bladder cancer.
13:230-238.
2019
-
Postoperative complications of hypospadias repair in patients receiving caudal block vs. non-caudal anesthesia: A meta-analysis.
13:E249-E257.
2019
-
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).
13:307-314.
2019
-
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.
13:166-174.
2019
-
Scrotal trauma: A case report and review of the literature.
13:S67-S71.
2019
-
Canadian Urological Association guideline on perioperative thromboprophylaxis and management of anticoagulation.
13:105-114.
2019
-
Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis.
13:15-23.
2019
-
Patient presentation, differential diagnosis, and management of penile lesions..
13:S2-S8.
2019
-
The QUEST for better marks.
13:43-44.
2019
-
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
12:328-336.
2018
-
Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
12:E281-97.
2018
-
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.
12:173-80.
2018
-
Canadian Urological Association/Pediatric Urologists of Canada guidelines on the investigation and management of antenatally detected hydronephrosis.
12:85-92.
2018
-
Transitioning patients with hypospadias and other penile abnormalities to adulthood: What to expect?.
12:S27-33.
2018
-
Compliance of the recurrent renal stone former with current best practice guidelines.
12:E112-20.
2018
-
Abridged version: CUA guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants.
12:18-28.
2018
-
CUA guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants.
12:E76-E99.
2018
-
Supplementary data: Testosterone suppression in the treatment of recurrent or metastatic prostate cancer – A Canadian consensus statement.
12:E45-6.
2018
-
Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement.
12:30-7.
2018
-
Images in urology: Localized primary amyloidosis of the urinary bladder.
12:E42-4.
2018
-
Positive surgical margin rates during the robot-assisted laparoscopic radical prostatectomy learning curve of an experienced laparoscopic surgeon.
11:E409-13.
2017
-
Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.
11:310-320.
2017
-
Video replay in surgery: Can we make the “right call” in predicting outcomes?.
11:337-337.
2017
-
Case: Anuria and acute renal failure post-endoscopic valve ablation and Foley catheter insertion in a newborn with a small-capacity, non-compliant bladder.
11:E382-4.
2017
-
Canadian Urological Association-Pediatric Urologists of Canada (CUA-PUC) guideline for the diagnosis, management, and followup of cryptorchidism.
11:E251-60.
2017
-
Case: Spontaneous regression of post-radical prostatectomy prostate-specific antigen elevation without adjuvant therapy in a patient with lymph node metastasis.
11:E315-7.
2017
-
Techniques: Utility of a 3D printed bladder model for teaching minimally invasive urethrovesical anastomosis.
11:E321-2.
2017
-
Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.
11:204-204.
2017
-
Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadian academic tertiary care centre.
11:174-174.
2017
-
Supplementary data: External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.
11:126-126.
2017
-
Antibiotic prophylaxis for prevention of urinary tract infections in prenatal hydronephrosis: An updated systematic review.
11:3-3.
2017
-
Can it wait? A systematic review of immediate vs. delayed surgical repair of penile fractures.
11:53-53.
2017
-
Continuous antibiotic prophylaxis in the setting of prenatal hydronephrosis and vesicoureteral reflux.
11:20-20.
2017
-
Cryptorchidism: A practical review for all community healthcare providers.
11:26-26.
2017
-
Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?.
11:39-39.
2017
-
Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline.
11:1-1.
2017
-
External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.
11:94-94.
2017
-
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.
11:112-112.
2017
-
Management of pelvic fracture-associated urethral injuries: A survey of Canadian urologists.
11:74-74.
2017
-
Striving to improve care for hypospadias patients.
11:54-54.
2017
-
Prostate cancer, ESMO 2016.
10:S231-S234.
2016
-
A prospective evaluation of obesometric parameters associated with renal stone recurrence.
10:234-234.
2016
-
Prostate volume estimations using magnetic resonance imaging and transrectal ultrasound compared to radical prostatectomy specimens.
10:264-264.
2016
-
Academic Urologist.
10:E213-E213.
2016
-
A proposed solution to a urological tightrope walk: The challenge of transition of spina bifida patients from pediatric to adult care in Ontario.
10:306-306.
2016
-
An unusual case of polyembolokoilamania: Urethral avulsion from foreign object use during sexual gratification.
10:181-181.
2016
-
Appendix for: "A proposed solution to a urological tightrope walk: The challenge of transition of spina bifida patients from pediatric to adult care in Ontario"n.
10:340-340.
2016
-
Complete resection of a primitive neuroectodermal tumour arising in the bladder of a 31-year-old female after neoadjuvant chemotherapy.
10:264-264.
2016
-
Contemporary agents in the management of metastatic castration-resistant prostate cancer.
10:414-414.
2016
-
Mitigating pelvic recurrence and improving overall survival.
10:95-95.
2016
-
Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline.
10:332-332.
2016
-
Prostate cancer, ESMO 2016.
10:331-331.
2016
-
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.
10:46-46.
2016
-
Survey on the perception of urology as a specialty by medical students.
10:349-349.
2016
-
2015 CUA Abstracts.
9:S13-S134.
2015
-
A resident’s perspective.
9:87-87.
2015
-
Angiosarcoma of the adrenal gland with concurrent contralateral advanced renal cell carcinoma: A diagnostic and management dilemma.
9:302-302.
2015
-
Capillary hemangioma of the testis: a rare benign tumor.
9:133-133.
2015
-
Development and incorporation of hybrid simulation OSCE into in-training examinations to assess multiple CanMEDS competencies in urologic trainees.
9:32-32.
2015
-
Follicle stimulating hormone (FSH): A potential surrogate marker for androgen deprivation therapy (ADT) oncological and systemic effects..
9:226-226.
2015
-
Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects.
9:E226-E227.
2015
-
Misuse of ultrasound for palpable undescended testis by primary care providers: A prospective study.
9:387-387.
2015
-
Perfect practice makes perfect.
9:336-336.
2015
-
Renal cell carcinoma and amyopathic dermatomyositis.
9:340-340.
2015
-
Simulation-based flexible ureteroscopy training using a novel ureteroscopy part-task trainer.
9:331-331.
2015
-
Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions.
9:275-275.
2015
-
The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC).
9:90-90.
2015
-
The relative contribution of urine extravasation to elevation of plasma creatinine levels in acute unilateral ureteral obstruction.
9:428-428.
2015
-
A survey of cannabis (marijuana) use and self-reported benefit in men with chronic prostatitis/chronic pelvic pain syndrome.
8:901-901.
2014
-
Development of a novel classification system for anatomical variants of the puboprostatic ligaments with expert validation.
8:432-432.
2014
-
Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib.
8:398-398.
2014
-
Impact of penile degloving and proximal ventral dissection on curvature correction in children with proximal hypospadias.
8:424-424.
2014
-
Pure laparoscopic unilateral nephrectomy for a patient with a polycystic horseshoe kidney.
8:881-881.
2014
-
The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence.
8:845-845.
2014
-
A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer.
8:583-583.
2014
-
Cost-effectiveness analysis reveals microsurgical varicocele repair is superior to percutaneous embolization in the treatment of male infertility.
8:619-619.
2014
-
2014 CUA Abstracts.
8:S25-S124.
2014
-
Academic transplant urologist.
8.
2014
-
Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review..
7:E783-E787.
2013
-
Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: a systematic review.
7:463-463.
2013
-
A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada.
7:335-335.
2013
-
Are Physicians Performing Neonatal Circumcisions Well Trained?.
7:260-260.
2013
-
CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update.
7:231-231.
2013
-
Conflicts of interest: CUA Guideline on managing CRPC.
7:301-301.
2013
-
Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney disease.
7:108-13.
2013
-
Defining a new testosterone threshold for medical castration: Results from a prospective cohort series.
7:263-263.
2013
-
Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.
7:411-411.
2013
-
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.
7:74-74.
2013
-
Learning curve for TIP urethroplasty: A single-surgeon experience.
7:789-789.
2013
-
Left behind: The potential problem of residual cancer.
7:39-39.
2013
-
Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
7:797-797.
2013
-
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
7:44-44.
2013
-
Positive surgical margins at radical prostatectomy: Population-based averages within PSA and Gleason strata.
7:561-561.
2013
-
The trend towards nephron-sparing procedures for renal masses: Surprisingly slow or reassuringly rapid?.
7:450-450.
2013
-
Transplant renal artery stenosis secondary to mechanical compression from polycystic kidney disease: A case report.
7:e251-3.
2013
-
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada..
6:455-462.
2012
-
Buried penis: An unrecognized risk factor in the development of invasive penile cancer..
6:E199-E202.
2012
-
Laparoscopic partial nephrectomy: The McMaster University experience.
6:233-237.
2012
-
Pre-treatment risk stratification of prostate cancer patients: A critical review.
6:121-127.
2012
-
Urothelial carcinoma involving the distal penis.
6:81-83.
2012
-
Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group.
5:379-381.
2011
-
A feasibility trial of a cognitive-behavioural symptom management program for chronic pelvic pain for men with refractory chronic prostatitis/chronic pelvic pain syndrome.
5:328-332.
2011
-
Commercial renal transplantation: A risky venture? A single Canadian centre experience.
5:335-340.
2011
-
Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.
5:274-282.
2011
-
The urologist: the life of the party.
5:186-187.
2011
-
Life before and after residents: subjective reports on quality of life from urologists since inception of a new residency program.
5:103-106.
2011
-
ADT and the metabolic syndrome: no good deed goes unpunished.
5:33-33.
2011
-
Development and validation of a virtual reality transrectal ultrasound guided prostatic biopsy simulator.
5:27-27.
2011
-
Lower abdominal mass in a 16-year old adolescent: an unusual presentation of posterior urethral valves.
5:e1-e3.
2011
-
Renal histopathology features according to various warm ischemia times in porcine laparoscopic and open surgery model.
5:40-43.
2011
-
Guidelines for the management of castrate-resistant prostate cancer.
4:380-384.
2010
-
A cost-analysis comparison of laparoscopic radical prostatectomy versus open radical prostatectomy:the McMaster Institute of Urology experience.
4:237-241.
2010
-
High-intensity focused ultrasound for prostate cancer: a practice guideline.
4:232-232.
2010
-
Outpatient tubeless percutaneous nephrolithotomy:the initial case series.
4:86-86.
2010
-
Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review.
4:201-201.
2010
-
Canadian consensus guidelines for the management of testicular germ cell cancer.
4:19-19.
2010
-
Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment.
4:50-50.
2010
-
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.
3:460-460.
2009
-
Management of the urethra in urothelial bladder cancer.
3.
2009
-
Management of the urethra in urothelial bladder cancer.
3:211-211.
2009
-
The case for prostate capsule-sparing radical cystectomy in selected patients.
3.
2009
-
The case for prostate capsule-sparing radical cystectomy in selected patients.
3:215-215.
2009
-
In favour of bladder preservation using combined modality treatment.
3:412-412.
2009
-
Use of an oncology sperm bank: a Canadian experience.
3:219-219.
2009
-
Task-specific bench model training versus basic laparoscopic skills training for laparoscopic radical prostatectomy: a randomized controlled study.
3:22-22.
2009
-
Treatment of adult rhabdoid renal cell carcinoma with sorafenib.
2:631-631.
2008
-
Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting.
2:500-500.
2008
-
Laparoscopic pyeloplasty: the updated McMaster University experience.
2:388-388.
2008
-
The Canadian Benign Prostatic Hyperplasia Audit Study (CanBas).
2:367-367.
2008
-
Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement.
2:175-175.
2008
-
Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement.
2:95-95.
2008
-
Factors predicting overall success: a review of 747 microsurgical vasovasostomies.
1:388-388.
2007
-
Long-term renal function and continence status in patients with.
1:371-371.
2007
-
The question of repeat biopsies.
1:250.
2007
-
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.
1:S28-S33.
2007
-
Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines.
1:S34-S40.
2007
-
Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline.
1:27-38.
2007
-
A cost-analysis comparison of laparoscopic radical prostatectomy versus open radical prostatectomy: the McMaster Institute of Urology experience.
4:237-237.
-
A feasibility trial of a cognitive-behavioural symptom management program for chronic pelvic pain for men with refractory chronic prostatitis/chronic pelvic pain syndrome.
5:328-328.
-
ADT and the metabolic syndrome: no good deed goes unpunished.
5:33-33.
-
CUAJ Correction October 2013.
7:301-301.
-
Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective.
5:379-379.
-
Guidelines for the management of castrate-resistant prostate cancer.
4:380-380.
-
Life before and after residents: subjective reports on quality of life from urologists since inception of a new residency program.
5:103-103.
-
Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.
5:274-274.
-
Pre-treatment risk stratification of prostate cancer patients:A critical review.
6.
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)